For the first time in Australia, a weight loss drug has been approved to also treat cardiovascular disease in overweight and obese patients. The ...

Semaglutide — the active ingredient in the brand-name meds Ozempic, Wegovy, and Rybelsus — treats type 2 diabetes and obesity ...

A recent study from the University of Pennsylvania has confirmed that the injectable medication semaglutide can lead to major ...

For the first time a semaglutide weight loss drug has been approved for use in Australia to also treat cardiovascular disease in obese and overweight patients.

The first clinical trial of its kind found the weekly semaglutide jab cuts the amount people drink in one day by 40 per cent ...

In 2022, when the surge in popularity of the GLP-1 class of weight loss and diabetes drugs really began, stories of surprise ...

Another weight-loss jab will hit pharmacy shelves in Ireland at the end of next month – but it will only be available on ...

Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of ...

Semaglutide's role extends beyond diabetes, aiding weight loss and offering cardiovascular protection, with ongoing research ...

WEIGHT-loss jabs are taking the world by storm, with a staggering half a million of us now using them. The injections have ...

Novo Nordisk shares tumbled last year when obesity candidate CagriSema failed to clear a weight loss bar of 25%. Now, ...